Cepharanthine, a Japanese prescription medicine made from a climbing plant and used for low white blood cell counts and hair loss, is now proposed to clear aged, inflammation-producing cells. All evidence for this comes from cell cultures, worms, fish and mice, mostly from one research group; no person has yet been tested. Decades of low-dose Japanese use suggest good short-term tolerance. It is a plausible but unproven candidate. (Full Review)

Protocol

Continuous low-dose approach (approved Japanese regimen)

1.5–2 mg/day alopecia; 3–6 mg/day leukopenia

In 2–3 divided doses after meals

Short high-dose courses tested in people

60 or 120 mg/day for 5 days

20 or 40 mg every 8 hours, in a COVID-19 trial; no senolytic protocol has been tested in humans

Intermittent "hit-and-run" approach

Brief course, then stop

Senolytic model, as with dasatinib plus quercetin for 3 days; no such cepharanthine regimen has been tested

Time to effect

Platelet recovery

By 12 months

Children with chronic immune thrombocytopenia; no control group

Senescent-cell clearance

Unknown in humans

Dasatinib plus quercetin: within 11 days of a 3-day course (report later corrected)

Benefits

Low: Prevention of treatment-induced leukopenia; hair regrowth in alopecia areata; platelet recovery in chronic immune thrombocytopenia; resolution of otitis media with effusion; recovery from mamushi snakebite; faster viral clearance in mild COVID-19

Speculative: Selective clearance of senescent cells; improved organ function and lifespan in aged animals; prevention of chemotherapy-induced senescence

Contraindications

Prior hypersensitivity to cepharanthine or product components

Pregnancy

Breastfeeding

Recent surgery or unhealed wounds

Active chemotherapy

Hemolytic anemia

Key Interactions

Theoretical (inferred from mechanism)

CYP3A4 substrates (tacrolimus, simvastatin)

CYP2C9 substrates (warfarin, phenytoin)

P-gp substrates (digoxin, dabigatran)

Antiplatelet and non-steroidal anti-inflammatory drugs (aspirin, ibuprofen)

Antiplatelet supplements (fish oil, ginkgo)

Other senolytics (dasatinib, quercetin)

Corticosteroids (methylprednisolone, prednisolone)

P-gp inducers (rifampicin, St John's wort)

Chemotherapy (doxorubicin, paclitaxel)

Surgery (other intervention)

Risk & Side Effects

Medium: Night sweats

Low: Gastrointestinal upset; hypersensitivity reactions including anaphylaxis; liver enzyme elevation; dizziness and headache; menstrual irregularities; injection-site pain

Speculative: Off-target death of healthy cells, including red blood cells; delayed wound healing from senescent-cell removal

Monitoring

Marker	Target	Why
ALT	7–55 U/L	Liver safety check
AST	8–48 U/L	Liver safety check
Hemoglobin	13.2–16.6 g/dL men; 11.6–15.0 g/dL women	Red-cell toxicity check
Reticulocyte count	Not specified in the ER	Follow-up if hemoglobin falls
IL-6	<6.4 pg/mL; track change from own baseline	Inflammatory signaling
p16INK4a	Not specified in the ER	Senescent-cell burden; research test only

Cadence: Baseline before a first course; repeat 2–4 weeks after the first course, then before each later course or every 3–6 months during repeated cycles

Qualitative Assessment

Energy and fatigue levels
Physical function, such as walking speed and stair climbing
Joint stiffness and pain
Sleep quality and night sweats
Gastrointestinal tolerance
Skin rash or itching

Cepharanthine as a Senolytic Therapy

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment